Aldurazyme laronidase: Phase I; Phase III ongoing

BRMN and partner Genzyme (GENZ, Cambridge, Mass.) reported in The New England Journal of Medicine results from an open label, 52-week U.S. Phase I trial of 125,000 IU/kg of Aldurazyme given i.v. once ...